Neurocrine Biosciences (NBIX) Assets Average (2011 - 2026)

Neurocrine Biosciences (NBIX) has reported Assets Average for 16 consecutive years, with $5.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 35.47% year-over-year to $5.1 billion; the trailing twelve-month figure through Jun 2026 stood at $5.1 billion (up 35.47% YoY), and the FY2025 full-year result was $4.2 billion, up 19.8% from the prior year.
• Assets Average improved to $5.1 billion in Q2 2026 per NBIX's latest filing, from $4.8 billion in the prior quarter.
• Across five years, Assets Average topped out at $5.1 billion in Q2 2026 and bottomed at $2.1 billion in Q3 2022.
• Historically, Assets Average has averaged $3.3 billion across 5 years, with a median of $3.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Assets Average gained 4.41% in 2022, then jumped 42.2% in 2024.
• Over 5 years, Assets Average stood at $2.3 billion in 2022, then surged by 35.18% to $3.0 billion in 2023, then rose by 18.92% to $3.6 billion in 2024, then gained by 22.66% to $4.4 billion in 2025, then advanced by 15.38% to $5.1 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $5.1 billion, $4.8 billion, and $4.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.